Abstract: Aspects of the present application relates to solid state forms of Pirtobrutinib such as novel crystalline form P1, amorphous solid dispersions comprising Pirtobrutinib and pharmaceutically acceptable carriers and processes thereof, wherein the pharmaceutically acceptable carrier is selected from the group consisting of HPMC phthalate, HPC, Eudragit L 100, microcrystalline cellulose, carboxymethyl cellulose, mannitol, Neusilin, cellulose acetate phthalate, polyvinyl alcohol, polylactic-co-glycolic acid, polyvinyl acetate phthalate, sodium alginate, beta cyclodextrin, and mixtures thereof. Aspects of the present application relates to process for the preparation of [(1S)-2,2,2-trifluoro-1-methyl-ethyl]hydrazine or its salts.

Abstract: The present invention provides a process for preparation of Elagolix and its intermediates, processes for preparation of amorphous Elagolix sodium and solid dispersion of Elagolix Sodium thereof.

Abstract: Aspects of the present application relate to solid forms of Venetoclax and preparative processes thereof. Specific aspects relate to an amorphous form of Venetoclax, its solid dispersion and crystalline forms of Venetoclax or salts thereof. Further aspects of the present application relate to processes for the preparation of Venetoclax.